Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPID | Q08752 | 3/20 | 0.50 |
| ▸ | PPIB | P23284 | 1/20 | 0.50 |
| ▸ | PPIA | P62937 | 1/20 | 0.50 |
| ▸ | PPIG | Q13427 | 1/20 | 0.50 |
| ▸ | LTA4H | P09960 | 4/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3912954 | 0.87 | MEN1 (0.44) | KMT2AALDH1A1HPGDMEP1BMEN1 | |
| SCHEMBL6325880 | 0.86 | LTA4H (0.47) | PPIDPPIBPPIAPPIGLTA4H | |
| SCHEMBL11954384 | 0.85 | KMT2A (0.53) | PPIDPPIBPPIAPPIGLTA4H | |
| SCHEMBL2036271 | 0.85 | PPID (0.71) | PPIDPPIBPPIAPPIGSMN1; SMN2 | |
| SCHEMBL8168973 | 0.84 | LTA4H (0.50) | LTA4HKMT2AALDH1A1MEN1 | |
| SCHEMBL23703051 | 0.83 | CYP1A2 (0.50) | PPIDLTA4HSMN1; SMN2KMT2AALDH1A1 | |
| SCHEMBL3168451 | 0.83 | HDAC1 (0.50) | PPIDLTA4HSMN1; SMN2KMT2AALDH1A1 | |
| SCHEMBL5182549 | 0.83 | PPID (0.49) | PPIDPPIBPPIAPPIGLTA4H | |
| SCHEMBL21391612 | 0.82 | PPID (0.71) | PPIDPPIBPPIAPPIGLTA4H | |
| SCHEMBL10011061 | 0.82 | MEN1 (0.60) | SMN1; SMN2KMT2AALDH1A1HPGDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111868617-B | Liquid crystal aligning agent, polymer for obtaining the same, liquid crystal alignment film, and liquid crystal display element using the same | 日产化学株式会社 | 2023-09-12 | — | — | CN | disclosed |
| CN-111868617-A | Liquid crystal aligning agent, polymer for obtaining the same, liquid crystal alignment film, and liquid crystal display element using the same | 日产化学株式会社 | 2020-10-30 | — | — | CN | disclosed |
| WO-2019182070-A1 | LIQUID CRYSTAL ALIGNING AGENT, POLYMER FOR OBTAINING SAME, LIQUID CRYSTAL ALIGNMENT FILM, AND LIQUID CRYSTAL DISPLAY ELEMENT USING SAME | 日産化学株式会社 | 2019-09-26 | — | — | WO | disclosed |
| US-6855710-B2 | Substituted indolines with an inhibitory effect on various kinases and complexes of CDKs | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-02-15 | — | — | US | disclosed |
| US-20040058978-A1 | Novel substituted indolines with an inhibitory effect on various kinases and complexes of CDKs | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2004-03-25 | — | — | US | disclosed |
| EP-1115704-B1 | NOVEL SUBSTITUTED INDOLINONES WITH AN INHIBITORY EFFECT ON VARIOUS KINASES AND CYCLIN/CDK COMPLEXES | BOEHRINGER INGELHEIM PHARMA (DE) | 2003-06-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058978-A1 | Novel substituted indolines with an inhibitory effect on various kinases and complexes of CDKs | CDK1, CDK2, CDK3 | PPID 3161/4885PPIB 3253/4885PPIA 2897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.